ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Nabil Rizk
Robert J. Downey
Manjit S. Bains
Valerie Rusch
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rizk, N.
Right arrow Articles by Rusch, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rizk, N.
Right arrow Articles by Rusch, V.
Related Collections
Right arrow Esophagus - cancer

Ann Thorac Surg 2006;81:1076-1081
© 2006 The Society of Thoracic Surgeons

Original article: General thoracic

Preoperative 18[F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival After Esophageal Adenocarcinoma Resection

Nabil Rizk, MD a , * , Robert J. Downey, MD a , Timothy Akhurst, MBBS, FRACP b , Mithat Gonen, PhD c , Manjit S. Bains, MD a , Steven Larson, MD b , Valerie Rusch, MD a

a Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
b Division Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
c Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

Accepted for publication September 22, 2005.

* Address correspondence to Dr Rizk, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021. (Email: rizkn{at}mskcc.org).

BACKGROUND: Clinical staging modalities for esophageal cancer are inaccurate at determining prognosis, especially in early-stage patients. We performed a retrospective review of patients with esophageal adenocarcinoma imaged by positron emission tomography before surgical resection to determine whether 18[F]-fluorodeoxyglucose uptake predicted overall survival independently of clinical and pathologic stage.

METHODS: The study is a retrospective review of patients with adenocarcinoma of the esophagus treated by surgery. All patients were imaged with computed tomography and positron emission tomography imaging, and most patients had an endoscopic ultrasound. We compared positron emission tomography standardized uptake values (SUVmax) with clinical and pathologic stage and survival. Prognostic variables were assessed by log-rank test, and survival by the method of Kaplan and Meier.

RESULTS: From January 1996 through June 2004, 50 patients meeting study eligibility criteria were analyzed. Median follow-up for surviving patients was 27 months. The median SUVmax was 4.5. Stratification of patients by the median SUVmax predicted survival. The 3-year survival was 57% for patients with an SUVmax greater than 4.5 and 95% for patients with an SUVmax of 4.5 or less (p = 0.02). The survival advantage of the SUVmax 4.5 or less group was also seen in clinically early-stage patients (defined as no adenopathy on computed tomography and positron emission tomography, and by endoscopic ultrasound T1–2 N0), as well as in patients with pathologically early-stage disease (T–2 N0).

CONCLUSIONS: In surgically managed esophageal adenocarcinoma patients, SUVmax predicts overall survival. Moreover, SUVmax identifies patients who have a poor prognosis from a subset of patients that would otherwise be considered to have early-stage disease.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
W.-H. Hsu, P.-K. Hsu, S.-J. Wang, K.-H. Lin, C.-S. Huang, C.-C. Hsieh, and Y.-C. Wu
Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma.
Ann. Thorac. Surg., May 1, 2009; 87(5): 1564 - 1568.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. D. Taylor, P. W. Smith, W. K. Brix, M. R. Wick, N. Theodosakis, B. R. Swenson, B. D. Kozower, and D. R. Jones
Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer
Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 699 - 705.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Guo, H. Zhu, Y. Xi, B. Zhang, L. Li, Y. Huang, J. Zhang, Z. Fu, G. Yang, S. Yuan, et al.
Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus
J. Nucl. Med., August 1, 2007; 48(8): 1251 - 1258.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
S. G. Little, T. W. Rice, B. Bybel, D. P. Mason, S. C. Murthy, G. W. Falk, L. A. Rybicki, and E. H. Blackstone
Is FDG-PET indicated for superficial esophageal cancer?
Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 791 - 796.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. M. Larson and L. H. Schwartz
18F-FDG PET as a Candidate for "Qualified Biomarker": Functional Assessment of Treatment Response in Oncology
J. Nucl. Med., June 1, 2006; 47(6): 901 - 903.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Piehler
Invited commentary
Ann. Thorac. Surg., March 1, 2006; 81(3): 1082 - 1082.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The Society of Thoracic Surgeons.